We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Roche has initiated Phase I trials of intrathecal ASO against ApoE for early Alzheimer's disease. Why this is a revolution, who will benefit, and hidden risks. Read the analysis.
